NCPA joined APhA and NACDS in a letter seeking clarification from the Drug Enforcement Administration regarding the 2022 version of the DEA Pharmacist’s Manual, which stated that the federal daily sales quantity limit of 3.6 grams applies when a pharmacist dispenses pursuant to a prescription pseudoephedrine that federally does not require a prescription. In the letter, we argued that it has been our understanding that the federal daily sales quantity limit does not apply when dispensing pseudoephedrine products pursuant to a prescription. We urged DEA to issue official guidance clarifying that the federal daily sales quantity limit of 3.6 grams does not apply when a pharmacist dispenses pseudoephedrine.
NCPA
